Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction -

- Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET -

Read more at globenewswire.com